Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Placebo-controlled, Phase IIb/Phase III Study to Evaluate the Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa. Lunsayil 1.

NCT05819398 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05819398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05819398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Placebo-controlled, Phase IIb/Phase III Study to Evaluate the Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa. Lunsayil 1.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2/3
Overall status
Completed
Start date
April 17, 2023
Completion date
March 31, 2025
Enrollment
209 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa